3-Iodothyronamine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| 3-Iodothyronamine | |
|---|---|
| |
| IUPAC name | 4-[4-(2-Amino-ethyl)-2-iodo-phenoxy]-phenol |
| Other names | T1AM |
| Identifiers | |
| CAS number | |
| SMILES | OC1=CC=C(OC2=C(I)C=C(CCN)C=C2)C=C1 |
| Properties | |
| Molecular formula | C14H14INO2 |
| Molar mass | 355.17 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
|
WikiDoc Resources for 3-Iodothyronamine | |
|
Articles | |
|---|---|
|
Most recent articles on 3-Iodothyronamine Most cited articles on 3-Iodothyronamine | |
|
Media | |
|
Powerpoint slides on 3-Iodothyronamine | |
|
Evidence Based Medicine | |
|
Cochrane Collaboration on 3-Iodothyronamine | |
|
Clinical Trials | |
|
Ongoing Trials on 3-Iodothyronamine at Clinical Trials.gov Trial results on 3-Iodothyronamine Clinical Trials on 3-Iodothyronamine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on 3-Iodothyronamine NICE Guidance on 3-Iodothyronamine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on 3-Iodothyronamine Discussion groups on 3-Iodothyronamine Patient Handouts on 3-Iodothyronamine Directions to Hospitals Treating 3-Iodothyronamine Risk calculators and risk factors for 3-Iodothyronamine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for 3-Iodothyronamine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
3-iodothyronamine (T1AM) is an endogenous thyronamine. T1AM is a high-affinity ligand for the trace amine-associated receptor TAAR1 (TAR1, TA1), a G protein-coupled receptor.[1] [1] In rodents, T1AM causes a rapid drop in body temperature when injected.
T1AM may be part of a signaling pathway to modulate cardiac function as the compound can induce negative inotropic effects and decrease cardiac output.[1]
See also
External links
References
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
